Drug slows cognitive decline in Alzheimer’s patients, study reveals

Antibody therapy lecanemab removes clumps of protein called beta amyloid that builds up in brain

• NHS nowhere near ready' to deliver new Alzheimer's drug, doctors say

Researchers have hailed the dawn of a new era of Alzheimer's therapies after a clinical trial confirmed that a drug slows cognitive decline in patients with early stages of the disease.

The result comes after decades of failure in the field and encouraged experts to say Alzheimer's - which affects 30 million people worldwide - could be treatable.